Background: Polycystic ovary syndrome (PCOS) is a leading cause of anovulatory subfertility. While letrozole is widely used for ovulation induction, treatment response varies and predictors beyond anti-Müllerian hormone (AMH) require further evaluation. This study aimed to investigate the association of demographic and clinical factors with ovarian response in subfertile PCOS patients treated with letrozole. Methods: A cross-sectional analytical study was conducted at the Center for Assisted Reproduction, BIRDEM-II Hospital, Dhaka, from April 2022 to September 2023. A total of 116 women with PCOS, aged 18–35 years, underwent letrozole induction (5 mg/day). Participants were categorized as responders (dominant follicle ≥16 mm, n=58) and non-responders (<16 mm, n=58). Demographic variables, BMI, type of subfertility, and baseline serum FSH and LH were compared between groups. Statistical analyses were performed using SPSS v26, with p<0.05 considered significant. Results: No significant associations were found between ovarian response and age (p=0.743), education (p=0.121), occupation (p=0.356), or income (p=0.576). BMI distributions did not differ significantly (p=0.331), nor did the type of subfertility (p=0.550). Serum FSH was significantly higher among non-responders (9.28±5.6 vs. 7.19±3.64, p<0.001), while serum LH showed no significant difference (p=0.102). Conclusion: Demographic and socioeconomic factors did not influence the ovarian response in patients with PCOS treated with letrozole. Elevated basal FSH levels were associated with poor responsiveness, indicating its role as a predictor. These findings support FSH assessment in individualized treatment planning for women with PCOS.